Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Erika Hamilton,Judy Sing-Zan Wang,Timothy J. Pluard,Stephen R. D. Johnston,Aki Morikawa,Elizabeth Claire Dees,Robert H. Jones,Barbara Haley,Anne C Armstrong,Adam L. Cohen,Pamela N. Munster,Gail Lynn Shaw Wright,Fadi Kayali,Manav Korpal,Jianjun (Alan) Xiao,Jenny Long,Benoit Destenaves,Lei Gao,Antonio Gualberto,Dejan Juric

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

2021

1018Background: H3B-6545, a selective, small molecule covalent antagonist of ERα demonstrated preclinical and preliminary clinical activity against ER+ breast cancer (Hamilton EP, SABCS, 2020). Thi...

Keywords:

Medicine
SERCA
Small molecule
advanced breast
Cancer
Estrogen receptor
Cancer research
Covalent bond
Breast cancer
Antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations